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PRIMERS AND PROBE TO IDENTIFY 
MYCOBACTERIUM TUBERCULOSIS 
COMPLEX 
FIELD OF THE INVENTION 
Methods and nucleic acids are disclosed for rapid, reli 
able, simple and highly sensitive detection of DNA of the 
Mycobacterium tuberculosis (MTB) complex With quanti 
tative real time PCR in formalin-?xed tissues. 
BACKGROUND OF THE INVENTION 
Rapid identi?cation of microbial pathogens has long been 
an important goal of diagnostic technology. In addition to 
identifying the pathogenic species, the clinician must noW 
af?rm the potential ef?cacy of standard antimicrobial treat 
ments early in the treatment of each case. Delays and 
erroneous results associated With conventional diagnostic 
tests frequently lead to the administration of ineffective 
treatments, Which in turn lead to complications, added costs, 
and poor outcomes. 
Tuberculosis (TB) kills 3,000,000 people in the World 
every year, more than AIDS, malaria, and other tropical 
diseases combined. One third of the World’s population is 
infected With tuberculosis and it represents more than a 
quarter of the World’s preventable deaths. The responsible 
mycobacteria are Gram-positive (no outer cell membrane), 
non-motile, pleomorphic rods, related to Actinomyces. 
Organisms of the Mycobacterium tuberculosis (MTB) 
complex are responsible for the signi?cant TB-associated 
morbidity and mortality observed in humans. The TB com 
plex consists of the folloWing species: M tuberculosis, M 
bovis, M bovis BCG, M. africanum, M microti, and M 
canetti. M. tuberculosis is the most common MTB complex 
pathogen isolated in humans. M bovis BCG may be trans 
mitted from infected animals to humans, M. africanum 
causes pulmonary tuberculosis in tropical Africa and M 
microti primarily infects animals. 
Tuberculosis is highly contagious, therefore rapid diag 
nosis of the disease is important. Classical methods for 
identi?cation of mycobacteria rely on staining specimens for 
acid fast bacilli folloWed by culture and biochemical testing. 
These cumbersome techniques render the identi?cation and 
quanti?cation of MTB complex pathogen very inef?cient. 
Therefore, although there are reports of PCR-based tests 
for diagnosis of TB, there is a continuing need for highly 
sensitive assays to rapidly detect the organisms causing TB. 
See Park et al., Arch Pathol Lab Med, Vol. 127, March 2003, 
pp. 326-330; Brisson-Noel et al., Lancet 1989; 211069-1071; 
Beige et al., J. Clin. Microbiol. 1995; 33:90-95; Perosio et 
al., Am. J. Clin. Pathol. 1993; 100:643-647; Hardman et al., 
Am. J. Clin. Pathol. 1996; 106:384-389; Salian et al.,Am. J. 
Respir. Crit. Care Med. 1998; 158:1150-1155; Vago et al., 
Am. J. Clin. Pathol. 1998; 109:411-415. 
All articles and patent documents cited herein are 
expressly incorporated by reference for their entirety for all 
purposes. 
SUMMARY OF THE INVENTION 
One aspect of the invention relates to an isolated oligo 
nucleotide of the sequence SEQ ID NO: 1. 
Another aspect of the invention relates to an isolated 
oligonucleotide that hybridiZes the complement of SEQ ID 
NO: 1 under stringent conditions and is capable of ampli 
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2 
fying MTB complex DNA When used in conjunction With 
SEQ ID NO: 2 in a polymerase chain reaction. 
Another aspect of the invention relates to an isolated 
oligonucleotide of the sequence of SEQ ID NO: 1, Wherein 
from about one to about three nucleotides are added or 
removed from the 5' end and/or from about one to about 
three nucleotides are added or removed from the 3' end, 
respectively, and Wherein the oligonucleotide is capable of 
amplifying MTB complex DNA When used in conjunction 
With SEQ ID NO: 2 in a polymerase chain reaction. 
Another aspect of the invention relates to an isolated 
oligonucleotide of the sequence SEQ ID NO: 2. 
Another aspect of the invention relates to an isolated 
oligonucleotide that hybridiZes the complement of SEQ ID 
NO: 2 under stringent conditions and is capable of ampli 
fying MTB complex DNA When used in conjunction With 
SEQ ID NO: 1 in a polymerase chain reaction. 
Another aspect of the invention relates to an isolated 
oligonucleotide of the sequence of SEQ ID NO: 2, Wherein 
from about one to about three nucleotides are added or 
removed from the 5' end and/or from about one to about 
three nucleotides are added or removed from the 3' end, 
respectively, and Wherein the oligonucleotide is capable of 
amplifying MTB complex DNA When used in conjunction 
With SEQ ID NO: 1 in a polymerase chain reaction. 
Another aspect of the invention relates to an isolated 
oligonucleotide having the sequence of SEQ ID NO: 3 or a 
sequence Wherein about one to about three nucleotides are 
added or removed from the 5' end and/ or about one to about 
three nucleotides are added or removed from the 3' end of 
SEQ ID NO: 3. 
Another aspect of the invention relates to a kit for 
detecting MTB complex DNA comprising a ?rst isolated 
oligonucleotide of SEQ ID NO: 1 or an oligonucleotide 
substantially identical thereto and a second oligonucleotide 
of SEQ ID NO: 2 or an oligonucleotide substantially iden 
tical thereto. In one embodiment of this aspect of the 
invention the kit further comprises oligonucleotide of the 
sequence of SEQ ID No: 3 or a sequence substantially 
identical thereto. 
Another aspect of the invention relates to a method of 
detecting the presence of MTB complex DNA in a biological 
sample comprising; obtaining a biological sample from an 
organism; isolating nucleic acids from the sample; perform 
ing a polymerase chain reaction on the isolated nucleic acids 
using as a forWard primer SEQ ID NO: 1 or an oligonucle 
otide substantially identical thereto and as a reverse primer 
SEQ ID NO: 2 or an oligonucleotide substantially identical 
thereto; and correlating a presence of an ampli?cation 
product from the polymerase chain reaction With the pres 
ence of MTB complex DNA in the sample. 
Another aspect of the invention relates to an method of 
identifying compounds capable of inhibiting groWth of 
MTB complex pathogen comprising: infecting a tissue cul 
ture With an MTB complex pathogen to obtain an infected 
tissue culture; contacting a portion of the infected tissue 
culture With a compound suspected of being capable of 
inhibiting MTB complex pathogen groWth; isolating nucleic 
acids from the portion of the infected tissue culture con 
tacted by the compound to obtain a ?rst nucleic acid sample 
and from a portion of the remainder of the infected tissue 
culture not contacted by the compound to obtain a second 
nucleic acid sample; performing polymerase chain reaction 
on the ?rst and the second nucleic acid samples using as a 
forWard primer SEQ ID NO: 1 or an oligonucleotide sub 
stantially identical thereto and as a reverse primer SEQ ID 
NO: 2 or an oligonucleotide substantially identical thereto; 
US 7,332,597 B2 
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whereby a decrease in an ampli?cation product in the ?rst 
nucleic acid sample relative to the second nucleic acid 
sample indicates that the compound is capable of inhibiting 
MTB complex pathogen groWth. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Schematic representation of the study design. 
MTB: Mycobaclerium tuberculosis; PCR: polymerase chain 
reaction; AFB: acid-fast bacilli. 
FIG. 2. Schematic representation of real-time procedure 
performed on microdissected formalin-?xed para?in embed 
ded (FFPE) tissue sections. 
FIG. 3. Q-PCR using MTB complex speci?c primers and 
probe performed on serial dilutions of formalin-?xed MTB 
DNA. 4000 to 0.04 pg4one organism equivalent4of DNA 
Were used (curves 1-6) as Well as a negative control (curve 
7). 
FIG. 4. Q-PCR using MTB complex speci?c primers and 
probe performed on atypical mycobacteria (M marinum, M 
avium, M cheloneae, M inlracellulare, M kansasii, M 
forluilum, M cheloneae subspecies abscessus, M Zerrae, M 
gordonae) and human DNA used as negative controls (NC), 
and DNA from cases l-3 in FIG. 5, that shoW a positive 
result. 
FIG. 5. Correlation of Q-PCR results on FFPE tissue 
sections positive for acid-fast bacilli and identi?cation of the 
organism by culture. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The invention relates to oligonucleotides and methods for 
the detection of Mycobaclerium tuberculosis complex 
(MTB) pathogen in a biological sample. Speci?cally, the 
oligonucleotides disclosed herein are useful for the ampli 
?cation of MTB DNA in biological samples, particularly in 
real-time polymerase chain reactions (PCR) performed on 
DNA isolated from formalin-?xed and para?in-embedded 
tissue samples. The oligonucleotides and methods disclosed 
herein are superior to those of the prior art because, for 
example, they enable the skilled artisan to detect a single 
copy of MTB complex DNA in a biological sample. 
“Nucleic acid” refers to a deoxyribonucleotide or ribo 
nucleotide polymer in either single- or double-stranded 
form, and unless otherWise limited, Would encompass 
knoWn analogs of natural nucleotides that can function in a 
similar manner as naturally occurring nucleotides. 
The term “oligonucleotide” refers to a molecule com 
prised of tWo or more deoxyribonucleotides or ribonucle 
otides, such as primers, probes, nucleic acid fragments to be 
detected, and nucleic acid controls. The exact siZe of an 
oligonucleotide depends on many factors and the ultimate 
function or use of the oligonucleotide. 
The term “primer” refers to an oligonucleotide, Whether 
natural or synthetic, capable of acting as a point of initiation 
of DNA synthesis under conditions in Which synthesis of a 
primer extension product complementary to a nucleic acid 
strand is induced, i.e., in the presence of four different 
nucleoside triphosphates and an agent for polymerization 
(i.e., DNA polymerase or reverse transcriptase) in an appro 
priate buffer and at a suitable temperature. A primer is 
preferably a single-stranded oligodeoxyribonucleotide. The 
appropriate length of a primer depends on the intended use 
of the primer but typically ranges from about 10 to about 30 
nucleotides. Short primer molecules generally require cooler 
temperatures to form su?iciently stable hybrid complexes 
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With the template. A primer need not re?ect the exact 
sequence of the template but must be su?iciently comple 
mentary to speci?cally hybridiZe With a template. When 
primer pairs are referred to herein, the pair is meant to 
include one forWard primer Which is capable of hybridiZing 
to the sense strand of a double-stranded target nucleic acid 
(the “sense primer”) and one reverse primer Which is 
capable of hybridiZing to the antisense strand of a double 
stranded target nucleic acid (the “antisense primer”). 
One aspect of the invention relates to oligonucleotide 
primers capable of acting as forWard primers in a PCR 
reaction for amplifying MTB complex DNA. Preferably, the 
forWard primer has the sequence: 5'-GACAACAAAGTTG 
GCCACCA-3' (SEQ ID NO: 1). 
Another aspect of the invention relates to oligonucleotide 
primers capable of acting as reverse primers in a PCR 
reaction for amplifying MTB complex DNA. Preferably, the 
reverse primer has the sequence: 5'-TGGGACAACAC 
CTGGAACAA-3' (SEQ ID NO: 2). 
Another aspect of the invention relates to oligonucleotide 
primers capable of acting as a probe for MTB complex 
DNA. Preferably, the probe has the sequence: 
5'-TTGGGTCCTGAGGCAACACTCGG-3' (SEQ ID NO: 
3). 
“Probe” refers to an oligonucleotide Which binds through 
complementary base pairing to a sub-sequence of a target 
nucleic acid. A primer may be a probe. It Will be understood 
by one of skill in the art that probes Will typically substan 
tially bind target sequences lacking complete complemen 
tarity With the probe sequence depending upon the strin 
gency of the hybridiZation conditions. The probes are 
typically directly labeled (e.g., With isotopes or ?uorescent 
moieties) or indirectly labeled such as With biotin to Which 
a streptavidin complex may later bind. By assaying for the 
presence or absence of the probe, one can detect the pres 
ence or absence of the target, by Southern blot for example. 
Preferably, the target is an ampli?cation product generated 
by PCR ampli?cation of MTB complex nucleic acids using 
primers SEQ ID NOs: l and 2, or oligonucleotides substan 
tially identical thereto, respectively. 
More, preferably, the probes are ?uorescently labeled and 
are capable of acting as a hydrolysis or Taqman® probes in 
a real-time PCR reaction to amplify MTB complex nucleic 
acids. The real-time PCR method uses a dual labelled 
?uorogenic oligonucleotide probe (i.e., the hydrolysis or 
TaqMan® probe) that anneals speci?cally Within the tem 
plate amplicon spanning the forWard (e.g. SEQ ID NO: 1) 
and reverse primers (e.g. SEQ ID NO: 2). Preferably, a 
?uorescent reporter molecule attached to 5'-position that 
?uoresces When released from probe by hydrolytic activity 
of DNA polymerase. Preferably, a quencher is attached to 
the 3' end of the probe. A quencher is a ?uorescent molecule 
that quenches (absorbs) the ?uorescence emission from the 
Reporter only When Reporter is attached to the probe before 
hydrolysis. Preferably, laser stimulation Within the capped 
Wells containing the reaction mixture causes emission of a 3' 
quencher dye (TAMRA) until the probe is cleaved by the 5' 
to 3' nuclease activity of the DNA polymerase during PCR 
extension, causing release of a 5' reporter dye (6FAM). 
Preferably, production of an amplicon causes emission of a 
?uorescent signal that is detected by a CCD (charge-coupled 
device) detection camera or other light capturing device, and 
the amount of signal produced at a threshold cycle Within the 
purely exponential phase of the PCR reaction, re?ects the 
starting copy number of the target sequence being ampli?ed. 
The invention also includes oligonucleotides substantially 
identical to SEQ ID NOs: l-3. For example, oligonucleotide 
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sequences substantially identical to SEQ ID NOs: l-3 may 
have several nucleotides added to or removed from their 5' 
ends or several nucleotides added to or removed from their 
3' ends. “Several nucleotides” in this context refers to about 
3 nucleotides, or preferably about tWo nucleotides or more 
preferably about one nucleotide. The person of skill in the art 
Will recognize that When adding nucleotides to the 5' and/or 
3' ends SEQ ID NOs: 1-3 the identity of those nucleotides 
may be dictated by the sequence of the MTB complex DNA 
to be ampli?ed. HoWever, the skilled artisan may also Wish 
to add overhangs to the 5' end of the forWard primer or 5' end 
of the reverse primer (giving a 3' sticky end on the ampli 
con). Such overhangs may include restriction enZyme sites 
useful in providing sticky ends to facilitate subcloning of the 
ampli?cation product, for example. 
Primers and probes of the invention exhibit an absence of 
hybridiZation to sequences contained in human RNA and 
DNA. This may be con?rmed theoretically by BLAST 
analysis (NCBI), and empirically by testing selected primer 
sets against human total nucleic acid under PCR conditions. 
Additionally, the claims probes and primers lack cross 
reactivity against other non-MTB complex pathogen 
genomes that could be present in clinical samples. This may 
also be con?rmed theoretically in a BLAST search, and 
empirically using genomic material from non-MTB com 
plex pathogen. 
For example, one of skill in the art Would envisage a 
genus of sequences substantially identical to SEQ ID NO: 1 
Wherein about one to about three nucleotides are added or 
removed from the 5' end and/or about one to about three 
nucleotides are added or removed from the 3' end, respec 
tively, to include but not be limited to the folloWing exem 
plary species: 
SEQ 
ID Sequence Substantially 
NO: Identical to SEQ ID NO: 1 Notes 
4 5 ' —GACAACAAAGTTGGCCAC—3 ' 2 nt removed from ' 3 
end 
5 5 ' —CAACAAAGTTGGCCACCA—3 ' 2 nt removed from 5 ' 
end 
6 5 ‘ —CAACAAAGTTGGCCAC—3 ‘ 2 nt removed from 5 ‘ 
end and 2 nt 
removed from ‘3 end 
'7 5 ' —ACAACAAAGTTGGCCACC—3 ' 1 nt removed from 5 ' 
end and 1 nt 
removed from ‘3 end 
8 5 ‘ —ACAACAAAGTTGGCCAC 1 nt removed from 5 ‘ 
CA-3 ‘ end 
9 5 ‘ —GACAACAAAGTTGGCCA 1 nt removed from ‘ 3 
CC-3 ‘ end 
10 5 ' —CAACAAAGTTGGCCACC—3 ' 2 nt removed from 5 ' 
end and 1 nt 
removed from ‘3 end 
11 5 ' —ACAACAAAGTTGGCCAC—3 ' 1 nt removed from 5 ' 
end and 2 nt 
removed from ‘3 end 
12 5 ' —TGACAACAAAGTTGGCCA 1 nt added to 5 ' 
CCA-3 ‘ end 
13 5 ' —GACAACAAAGTTGGCCAC 1 nt added to ' 3 end 
CAA-3 ' 
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— cont inued 
SEQ 
ID Sequence Substantially 
NO: Identical to SEQ ID NO: 1 Notes 
14 5 ' —GAAATTCGACAACAAAGTT ECORI site added to 
GGCCACCA-3 ' 5' end 
Additionally, one of skill in the art Would envisage a 
genus of sequences substantially identical to SEQ ID NO: 2 
Wherein about one to about three nucleotides are added or 
removed from the 5' end and/or about one to about three 
nucleotides are added or removed from the 3' end, respec 
tively, to include but not be limited to the folloWing exem 
plary species: 
SEQ 
ID Sequence Substantially 
NO: Identical to SEQ ID NO: 2 Notes 
15 5 ' —TGGGACAACACCTGGAAC—3 ' 2 nt removed from ' 3 
end 
16 5 ' —GGACAACACCTGGAACAA—3 ' 2 nt removed from 5 ' 
end 
17 5 ‘ —GGACAACACCTGGAAC—3 ‘ 2 nt removed from 5 ‘ 
end and 2 nt 
removed from ‘3 end 
18 5 ' —GGGACAACACCTGGAACA—3 ' 1 nt removed from 5 ' 
end and 1 nt 
removed from ‘3 end 
19 5 ' —GGGACAACACCTGGAACAA—3 ' 1 nt removed from 5 ' 
end 
20 5 ' —TGGGACAACACCTGGAACA—3 ' 1 nt removed from ' 3 
end 
21 5 ' —GGACAACACCTGGAACA—3 ' 2 nt removed from 5 ' 
end and 1 nt 
removed from ‘3 end 
22 5 ' —GGGACAACACCTGGAAC—3 ' 1 nt removed from 5 ' 
end and 2 nt 
removed from ‘3 end 
23 
24 
25 
5 ' —GTGGGACAACACCTGGAAC 
AA-3 ' 
5 ' —TGGGACAACACCTGGAACA 
AG-3 ' 
5 ' —GAAATTCTGGGACAACACCTGG 
AACAA-3 ' 
1 nt added to 
end 
1 nt added to 
end 
5 v 
' 3 
EcoRI site added to 
5' end 
Finally, one of skill in the art Would envisage a genus of 
sequences substantially identical to SEQ ID NO: 3 Wherein 
about one to about three nucleotides are added or removed 
from the 5' end and/or about one to about three nucleotides 
are added or removed from the 3' end, respectively, to 
include but not be limited to the folloWing exemplary 
species: 
US 7,332,597 B2 
SEQ 
ID Sequence Substantially 
NO: Identical to SEQ ID NO: 3 Notes 
26 5 ‘ —TTGGGTCCTGAGGCAACACT 2 nt removed from ‘ 3 
C-3 ‘ end 
27 5 ‘ —GGGTCCTGAGGCAACACTC 2 nt removed from 5 ‘ 
GG-3 ‘ end 
28 5 ‘ —GGGTCCTGAGGCAACACTC—3 ‘ 2 nt removed from 5 ‘ 
end and 2 nt 
removed from ‘3 end 
29 5‘ —TGGGTCCTGAGGCAACACT 1 nt removed from 5‘ 
CG-3‘ end and 1 nt 
removed from ‘3 end 
30 5‘ —TGGGTCCTGAGGCAACACTC 1 nt removed from 5‘ 
GG-3‘ end 
31 5‘ —TTGGGTCCTGAGGCAACAC 1 nt removed from ‘3 
TCG-3 ‘ end 
32 5‘ —GGGTCCTGAGGCAACACT 2 nt removed from 5‘ 
CG-3‘ end and 1 nt 
removed from ‘3 end 
33 5‘ —TGGGTCCTGAGGCAACACTC—3 ‘ 1 nt removed from 5‘ 
end and 2 nt 
removed from ‘3 end 
34 5‘ —GTTGGGTCCTGAGGCAACAC 1 nt added to 5‘ 
end 
35 5‘ —TTGGGTCCTGAGGCAACACTC 
GGA-3 ‘ 
1 nt added to ‘3 
end 
The skilled artisan Will also appreciate that oligonucle 
otide sequences substantially identical to SEQ ID NOs: 1-3 
may differ from SEQ ID NOs: 1-3, respectively, With respect 
to the identity of at least one nucleotide base. However, all 
oligonucleotides sequences substantially identical to SEQ 
ID NOs: 1-3 Will hybridize under stringent conditions (as 
de?ned herein) to all or a portion of the complements of 
SEQ ID NOs: 1-3 (i.e., target sequences), respectively. The 
terms “hybridize(s) speci?cally” or “speci?cally 
hybridize(s)” refer to complementary hybridization betWeen 
an oligonucleotide (e.g., a primer or labeled probe) and a 
target sequence. The term speci?cally embraces minor mis 
matches that can be accommodated by reducing the strin 
gency of the hybridization media to achieve the desired 
priming for the PCR polymerases or detection of hybridiza 
tion signal. 
Under stringent hybridization conditions, only highly 
complementary, i.e., substantially identical nucleic acid 
sequences, hybridize. Preferably, such conditions prevent 
hybridization of nucleic acids having 3 or more mismatches 
out of 20 contiguous nucleotides, more preferably 2 or more 
mismatches out of 20 contiguous nucleotides, most prefer 
ably one or more mismatch out of 20 contiguous nucle 
otides. The hybridizing portion of the hybridizing nucleic 
acid is at least about 90%, preferably at least about 95%, or 
most preferably about at least about 98%, identical to the 
sequence of a target sequence, or its complement. 
Hybridization of a nucleic acid to a nucleic acid sample 
under stringent conditions is de?ned beloW. Nucleic acid 
duplex or hybrid stability is expressed as a melting tem 
perature (Tm), Which is the temperature at Which the probe 
dissociates from the target DNA. This melting temperature 
is used to de?ne the required stringency conditions. If 
sequences are to be identi?ed that are substantially identical 
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to the probe, rather than identical, then it is useful to ?rst 
establish the loWest temperature at Which only homologous 
hybridization occurs With a particular concentration of salt 
(eg SSC or SSPE). Then assuming that 1% mismatching 
results in a 1° C. decrease in Tm, the temperature of the ?nal 
Wash in the hybridization reaction is reduced accordingly 
(for example, if sequences having >95% identity With the 
probe are sought, the ?nal Wash temperature is decrease by 
50 C.). In practice, the change in Tm can be between 05° C. 
and 15° C. per 1% mismatch. 
Stringent conditions involve hybridizing at 68° C. in 
5><SSC/5>< Denhart’s solution/1.0% SDS, and Washing in 
0.2><SSC/0.1% SDS at room temperature. Moderately strin 
gent conditions include Washing in 3><SSC at 42° C. The 
parameters of salt concentration and temperature be varied 
to achieve optimal level of identity betWeen the primer and 
the target nucleic acid. Additional guidance regarding such 
conditions is readily available in the art, for example, 
Sambrook, Fischer and Maniatis, Molecular Cloning, a 
laboratory manual, (2nd ed.), Cold Spring Harbor Labora 
tory Press, NeW York, (1989) and F. M. Ausubel et al eds., 
Current Protocols in Molecular Biology, John Wiley and 
Sons (1994). 
The sequences 5'-CAACAAAGTTGGCCA-3' (SEQ ID 
NO: 36) and 5'-CATGACAACAAAGTTGGCCA-3' (SEQ 
ID NO: 37) are explicitly excluded as sequences substan 
tially similar to SEQ ID NO: 1. Additionally, 5'-GGTGG 
GACAACACCTGGAAC-3' (SEQ ID NO: 38), 5'-ACAA 
CACCTGGA-3' (SEQ ID NO: 39), and 
5'-CAACACCTGGAA-3' (SEQ ID NO: 40) are explicitly 
excluded as sequences substantially similar to SEQ ID NO: 
2. 
Another aspect of the invention relates to a kit for 
detecting MTB complex DNA having SEQ ID NOs: 1 and 
2 or oligonucleotides substantially identical thereto. One 
embodiment of this aspect of the invention utilizes real-time 
PCR and includes SEQ ID NO: 3 or a oligonucleotides 
substantially identical thereto. 
Another aspect of the invention relates to a method of 
detecting MTB complex DNA by using SEQ ID NOs: 1 and 
2; or oligonucleotides substantially identical thereto, in a 
polymerase chain reaction performed on a biological 
sample. 
The present methods and oligonucleotides can be applied 
to any type of biological sample that is suspected of con 
taining MTB complex DNA. The term “biological sample” 
refers to a sample comprising any biological material (e.g., 
biological ?uids or tissues) containing nucleic acids. Bio 
logical samples can include tissue samples, Whole blood or 
serum, sputum, stool, urine, semen, pericardial ?uid, 
nasopharyngeal/throat sWabs, cerebrospinal ?uid (CSF), 
amniotic ?uid and the like. Alternatively, tissues may, for 
example, be surgically resected from a patient in the form of 
a biopsy or autopsy tissue sample. Preferably, at least about 
50 mg of tissue is resected. 
Most preferably, the tissue to be analyzed is in the form 
of, or contains a granuloma. Preferably, granulomas are 
aggregates of particular types of chronic in?amatory cells 
Which form nodules in the millimeter size range. Granulo 
mas may be con?uent, forming larger areas. Granuloma 
have collections of modi?ed macrophages, termed epithe 
lioid cells, usually With a surrounding zone of lymphocytes. 
Epithelioid cells are so named by tradition because of their 
histological resemblance to epithelial cells, but are not in 
fact epithelial; they are derived from blood monocytes, like 
all macrophages. Epithelioid cells are less phagocytic than 
other macrophages and appear to be modi?ed for secretory 
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functions. Macrophages in granulomas are commonly fur 
ther modi?ed to form multinucleate giant cells. These arise 
by fusion of epithelioid macrophages Without nuclear or 
cellular division forming huge single cells Which may con 
tain dozens of nuclei. In some circumstances the nuclei are 
arranged around the periphery of the cell, termed a Lang 
hans-type giant cell (characteristically seen in tuberculosis); 
in other circumstances the nuclei are randomly scattered 
throughout the cytoplasmifor example in the foreign body 
type of giant cell Which is formed in response to the presence 
of other indigestible foreign material in the tissue. Areas of 
granulomatous in?ammation commonly undergo necrosis. 
The prototype example here is caseous necrosis in tubercu 
losis. 
Generally microscale amounts of tissue are needed to 
detect MTB complex DNA. Preferably, a scrape of tissue 
from a pathological sample is used. More preferably, for 
malin-?xed and paraffin-embedded tissues are sectioned at a 
thickness of a 3 to 4 um, and nucleic acids are isolated from 
a 0.2 cm by 0.2 cm area of the tissue section. 
To amplify a target nucleic acid sequence in a sample by 
PCR, the sequence must be accessible to the components of 
the ampli?cation system. In general, this accessibility is 
ensured by isolating the nucleic acids from the sample. A 
variety of techniques for extracting nucleic acids, in par 
ticular deoxyribonucleic acids, from biological samples are 
knoWn in the art. Alternatively, if the sample is fairly readily 
disruptable, the nucleic acid need not be puri?ed prior to 
ampli?cation by the PCR technique, i.e., if the sample is 
comprised of cells, particularly peripheral blood lympho 
cytes or monocytes, lysis and dispersion of the intracellular 
components may be accomplished merely by suspending the 
cells in hypotonic buffer. 
If it is not possible to extract DNA from the tissue sample 
soon after its resection, the sample may be ?xed or frozen. 
DNA extracted and isolated from frozen or fresh samples of 
resected tissue is extracted by any method knoWn in the art, 
for example, Sambrook, Fischer and Maniatis, Molecular 
Cloning, a laboratory manual, (2nd ed.), Cold Spring Harbor 
Laboratory Press, NeW York, (1989). Preferably, care is 
taken to avoid degradation of DNA during the extraction 
process. 
Alternatively, tissue obtained from the patient may be 
?xed, preferably by formalin (formaldehyde) or gluteralde 
hyde treatment, for example. Biological samples ?xed by 
alcohol immersion are also contemplated in the present 
invention. Fixed biological samples are often dehydrated 
and embedded in paraf?n or other solid supports knoWn to 
those of skill in the art. Such solid supports are envisioned 
to be removable With organic solvents, alloWing for subse 
quent rehydration of preserved tissue. Fixed and paraffin 
embedded (FPE) tissue specimen as described herein refers 
to storable or archival tissue samples. 
DNA may be extracted from the FPE specimen by any of 
the methods as described in US. Pat. No. 6,428,963, Which 
is hereby incorporated by reference in its entirety. Most 
preferably, total DNA is extracted from granulomas from a 
formalin-?xed and paraffin-embedded tissue specimen. 
In an embodiment of the invention, DNA is isolated from 
an archival pathological sample or biopsy Which is ?rst 
deparaf?nized. An exemplary deparaf?nization method 
involves Washing the paraf?nized sample With an organic 
solvent, such as xylene. Deparaf?nized samples can be 
rehydrated With an aqueous solution of a loWer alcohol. 
Suitable loWer alcohols, for example include, methanol, 
ethanol, propanols, and butanols. Deparaf?nized samples 
may be rehydrated With successive Washes With loWer 
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alcoholic solutions of decreasing concentration. Altema 
tively, the sample is simultaneously deparaf?nized and rehy 
drated. 
Once the sample is reyhdrated, DNA is extracted and 
isolated from the rehydrated tissue. Deparaf?nized samples 
can be homogenized using mechanical, sonic or other means 
of homogenization, eg by laser microdisection. In one 
embodiment, rehydrated samples are homogenized in a 
solution comprising a chaotropic agent, such as guanidinium 
thiocyanate (also sold as guanidinium isothiocyanate). 
Chaotropic agents include but not limited to: guanidinium 
compounds, urea, formamide, potassium iodiode, potassium 
thiocyantate and similar compounds. The preferred chaotro 
pic agent for the methods of the invention is a guanidinium 
compound, such as guanidinium isothiocyanate (also sold as 
guanidinium thiocyanate) and guanidinium hydrochloride. 
Many anionic counterions are useful, and one of skill in the 
art can prepare many guanidinium salts With such appropri 
ate anions. The effective concentration of guanidinium solu 
tion used in the invention generally has a concentration in 
the range of about 1 to about 5M With a preferred value of 
about 4M. If RNA is already in solution, the guanidinium 
solution may be of higher concentration such that the ?nal 
concentration achieved in the sample is in the range of about 
1 to about 5M. The guanidinium solution also is preferably 
buffered to a pH of about 3 to about 6, more preferably about 
4, With a suitable biochemical bulfer such as Tris-Cl. The 
chaotropic solution may also contain reducing agents, such 
as dithiothreitol (DTT), ([3-mercaptoethanol; BME); and 
combinations thereof. The chaotropic solution may also 
contain RNAse and/or DNAase inhibitors. 
Commercially available kits are also readily available to 
isolate nucleic acids from various tissues. For example, such 
kits are available from Qiagen, Inc. (Valencia, Calif.). 
DNA is then recovered from the solution by, for example, 
phenol chloroform extraction, ion exchange chromatogra 
phy or size-exclusion chromatography. DNA may then be 
further puri?ed using the techniques of extraction, electro 
phoresis, chromatography, precipitation or other suitable 
techniques. 
The ampli?cation of MTB complex DNA from isolated 
total DNA from a fresh, frozen or ?xed biological sample is 
preferably carried out using polymerase chain reaction 
(PCR) methods common in the art. The ?rst step of each 
cycle of the PCR involves the separation of the nucleic acid 
duplex formed by the primer extension. Once the strands are 
separated, the next step in PCR involves hybridizing the 
separated strands With primers that ?ank the target sequence 
e.g. SEQ ID NOs: l and 2. The primers are then extended to 
form complementary copies of the target strands. For suc 
cessful PCR ampli?cation, the primers are designed so that 
the position at Which each primer hybridizes along a duplex 
sequence is such that an extension product synthesized from 
one primer, When separated from the template (comple 
ment), serves as a template for the extension of the other 
primer. The cycle of denaturation, hybridization, and exten 
sion is repeated as many times as necessary to obtain the 
desired amount of ampli?ed nucleic acid. Strand separation 
is achieved by heating the reaction to a suf?ciently high 
temperature for a suf?cient time to cause the denaturation of 
the duplex but not to cause an irreversible denaturation of 
the polymerase (see US. Pat. No. 4,965,188). Template 
dependent extension of primers in PCR is catalyzed by a 
polymerizing agent in the presence of adequate amounts of 
four deoxyribonucleoside triphosphates (typically dATP, 
dGTP, dCTP, dUTP and dTTP) in a reaction medium com 
prised of the appropriate salts, metal cations, and pH bulf 
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ering system. Suitable polymerizing agents are enzymes 
known to catalyze template-dependent DNA synthesis. For 
example, T hermus lhermophilus (Tth) DNA polymerase, a 
therrnostable DNA polymerase by Roche Molecular Sys 
tems (Alameda, Calif.) PCR is most usually carried out as an 
automated process With a therrnostable enzyme. In this 
process, the temperature of the reaction mixture is cycled 
through a denaturing region, a primer annealing region, and 
an extension reaction region automatically. Equipment spe 
ci?cally adapted for this purpose is commercially available 
from Roche Molecular Systems. 
Most preferably, ampli?cation of MTB complex DNA 
RNA is carried out using a ?uorescence based real-time 
detection method (e.g. SmartCycler®, Cepheid, or the ABI 
PRISM 7700 or 7900 Sequence Detection System [Taq 
Man®], Applied Biosystems, Foster City, Calif.) or similar 
system as described by Heid et al., (Genome Res 1996; 
61986-994) and Gibson et al.(Genome Res 1996; 6:995 
1001). This methodology is also referred to interchangeably 
herein as “real-time PCR” or “Q-PCR” Where “Q” stands for 
quanitative. The output of the ABI 7700 (TaqMan® Instru 
ment) is expressed in CT’s or “cycle thresholds”. A higher 
number of target molecules in a sample generates a signal 
With feWer PCR cycles (loWer CT) than a sample With a 
loWer number of target molecules (higher CT). By extension, 
given a set number of cycles, the level of ?uorescence 
generated in the reaction Will be indicative of the amount of 
ampli?cation product Which in turn, is a function of the 
amount template nucleic acid in the original biological 
sample. Therefore, real-time PCR also alloWs for the quan 
ti?cation of template DNA in the original biological sample. 
Preferably, the hydrolysis or TaqMan® probe for the oligo 
nucleotide primer pair SEQ ID NO: 1 and 2, is SEQ ID NO: 
3. 
One of skill Will recognize, hoWever, that the oligonucle 
otides of the invention are useful for quantifying MTB 
complex DNA by any knoWn method, such as ligase chain 
reaction (LCR) or self-sustained sequence replication, each 
of Which provides su?icient ampli?cation. Additionally, the 
present invention envisages the quanti?cation of MTB DNA 
via use of a PCR-free system employing, for example 
?uorescent labeled probes similar to those of the Invader® 
Assay (Third Wave Technologies, Inc.). 
As used herein, a “intemal control DN is meant to 
include DNA Whose presence in a biological sample enables 
an assessment of MTB complex DNA levels. Preferably, 
ampli?cation of MTB complex DNA in a biological sample 
is conducted in parallel, ie at the same time, With ampli 
?cation of internal control DNA. This alloWs for a determi 
nation of the overall amount of DNA in the sample and a 
control for variations in DNA recovery. “Intemal controls” 
can include, but are not limited to the cyclophilin gene, 
[3-actin gene, the transferrin receptor gene, GAPDH gene, 
and the like. Most preferably, the internal control DNA is a 
portion of the GAPDH gene. 
Another aspect of the invention relates to a method of 
identifying compounds capable of inhibiting the groWth of 
MTB complex pathogen. The method generally entails 
infecting a tissue culture With an MTB complex pathogen 
and then contacting a portion of the infected tissue culture 
With a compound suspected of being capable of inhibiting 
MTB complex pathogen groWth. Next nucleic acids are 
isolated from the portion of the infected tissue culture 
contacted by the candidate compound. As a control, nucleic 
acids are also isolated from a portion of the remainder of the 
infected tissue culture not contacted by the candidate com 
pound. Next, PCR is performed on both nucleic acid 
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samples in parallel. Preferably, SEQ ID NO: 1 or an oligo 
nucleotide substantially identical thereto is used as the 
forWard primer and SEQ ID NO: 2 or an oligonucleotide 
substantially identical thereto is used as the reverse primer. 
A decrease in ampli?cation product in the nucleic acid 
sample derived from the treated tissue culture relative to an 
amount of ampli?cation product in the nucleic acid sample 
derived from the control indicates that a candidate com 
pound is capable of inhibiting MTB complex pathogen 
groWth. MTB complex pathogen may be cultured in 
MB/BacT bottle according to manufacturer instruction or on 
LoWeinstein-Jensen (LI) slants prepared media (Oxoid). 
More preferably, the tissue culture comprises the human 
alveolar epithelial cell line A549. Additionally, the term 
“tissue culture” as used herein is not limited to in vitro uses. 
The term also encompasses live animals that act as incuba 
tors for MTB complex pathogen groWth such as suckling 
mice, rats or other mammals. 
Additional advantages of the present invention Will 
become readily apparent to those skilled in this art from the 
folloWing detailed description, Wherein only the preferred 
embodiment of the invention is shoWn and described, simply 
by Way of illustration of the best mode contemplated of 
carrying out the invention. As Will be realized, the invention 
is capable of other and different embodiments, and its 
several details are capable of modi?cations in various obvi 
ous respects, all Without departing from the invention. The 
present invention may be practiced Without some or all of 
these speci?c details. In other instances, Well knoWn process 
operations have not been described in detail, in order not to 
unnecessarily obscure the present invention. Accordingly, 
the draWings and description are to be regarded as illustra 
tive in nature, and not as restrictive. 
EXAMPLE 1 
Mycobacterial DNA extraction procedure (Epicenter 
Technologies MasterPure Puri?cation Kit Masidon, Wis.) 
1. Control strains of mycobacteria Were groWn on L] 
slants Were ?xed in 10% Formalin for at least 1 Week before 
processing. 
2. The formalin Was then aspirated off using sterile plastic 
transfer pipettes into a 50 ml conical tube. 
3. The slants Were Washed 3 times With sterile saline, each 
time the saline being transferred into 50 ml conical tubes. 
4. The ?nal aliquot of saline Was added to the slant, and 
the organism groWth Was scraped from the surface and 
suspended in the saline. 
5. The suspension Was alloWed to rest for at least 10 
minutes to alloW the larger particles to precipitate. 
6. The remaining ?uid containing the ?xed mycobacteria 
Was transferred to 2 ml conical tubes 
7. The mycobacteria Were alloWed to settle out overnight. 
8. Still under the biological safety cabinet, the saline Was 
aspirated from the pellet and the solubilizing agent Was 
added to the tubes. Each tube contained the folloWing: 
a. 900 uL of 2x Tissue and Cell Lysis buffer 
b. 6 uL of Proteinase K (50 uG/mL) 
9. The tubes Were incubated for 20 minutes at 680 C., 
inverting the tubes tWice during the heating process. 
10. The tubes Were chilled on ice for 5 minutes 
11. 450 uL of MCP solution Was added to each tube and 
the tubes vortexed 
12. The tubes Were then centrifuged in the microfuge 
13. The supernatant Was transferred into a clean 
microfuge tube 
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14. 500 uL of isopropanol Was added to each tube and the 
tubes inverted 30-40 times 
15. The tubes Were frozen over night at —200 C. 
16. The DNA Was pelleted for 10 minutes in a microfuge 
17. The DNA pellet Was rinsed With 75% EtOH 
18. The pellet Was drained and dried thoroughly 
19. The DNA Was resuspended in 35 uL of TE Buifer 
The DNA Was frozen at —200 C. until used for PCR 
ampli?cation. Atypical (non-TB) mycobacterial strains used 
as negative controls: 
Mycobaclerium marinum ATCC 927 
M avium ATCC 25291 
M cheloneae ATCC 19233 
M inlracullulare ATCC 13950 
M kansasii ATCC 12498 
M forluilum ATCC 6841 
M cheloneae subspecies abscessus CDC strain from 2001 
M Zerrae UK strain from 1988 
M gordonae ATCC 14470 
EXAMPLE 2 
Design: Serial dilutions of formalin-?xed MTB complex 
DNA, other mycobacterial DNA and DNA from microdis 
sected formalin-?xed paraffin-embedded tissue sections 
diagnosed as necrotizing granulomatous in?ammation With 
acid-fast bacilli Were used as templates for a PCR assay. 
Serial dilutions of ?xed MTB complex DNA Were prepared 
such that the highest dilution had only one copy of MTB 
complex DNA. The ?xed tissue sections used Were selected 
such that culture results Were available for each case. Results 
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of the real-time quantitative PCR assay using the primer pair 
SEQ ID NOs: 1 and 2 With the probe SEQ ID NO: 3, Were 
correlated the culture results for the ?xed tissue samples. 
GAPDH DNA Was used as an internal control for the assay 
performed on the ?xed tissue samples. 
Results: All serial dilutions of MTB complex DNA Were 
positive by this assay, including the highest dilution With 
only one copy of MTB complex DNA. FIG. 2. There Was no 
cross reactivity With other mycobacterial or human DNA. 
FIG. 3. All cases positive for MTB by PCR on ?xed tissue 
sections Were also positive by culture. No MTB culture 
positive cases Were missed by the assay. All cases negative 
for MTB by PCR on ?xed tissue sections Were also negative 
for the organism complex by culture. FIGS. 4 and 5. 
Conclusion: The real-time quantitative PCR assay is 
rapid, speci?c and highly sensitive for identi?cation of MTB 
in formalin-?xed paraffin-embedded tissue sections. It is 
technically simple and can be used in routine pathology 
practice. 
In this disclosure there is described only the preferred 
embodiments of the invention and but a feW examples of its 
versatility. It is to be understood that the invention is capable 
of use in various other combinations and environments and 
is capable of changes or modi?cations Within the scope of 
the inventive concept as expressed herein. Thus, for 
example, those skilled in the art Will recognize, or be able to 
ascertain, using no more than routine experimentation, 
numerous equivalents to the speci?c substances and proce 
dures described herein. Such equivalents are considered to 
be Within the scope of this invention. 
SEQUENCE LISTING 
SEQ ID NO 1 
LENGTH: 20 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l 
gacaacaaag ttggccacca 
SEQ ID NO 2 
LENGTH: 20 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 2 
tgggacaaca cctggaacaa 
SEQ ID NO 3 
LENGTH: 23 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 3 
ttgggtcctg aggcaacact cgg 23 
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SEQ ID NO 4 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: 4 
gacaacaaag ttggccac 
SEQ ID NO 5 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: 5 
caacaaagtt ggccacca 
SEQ ID NO 6 
LENGTH: 16 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: 6 
caacaaagtt ggccac 
SEQ ID NO '7 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: '7 
acaacaaagt tggccacc 
SEQ ID NO 8 
LENGTH: 19 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: 8 
acaacaaagt tggccacca 
SEQ ID NO 9 
LENGTH: 19 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
SEQUENCE: 9 
gacaacaaag ttggccacc 
SEQ ID NO 10 
LENGTH: 17 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
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<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: lO 
caacaaagtt ggccacc 
<2lO> SEQ ID NO 11 
<2ll> LENGTH: 17 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: ll 
acaacaaagt tggccac 
<2lO> SEQ ID NO 12 
<2ll> LENGTH: 21 
<2l2> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l2 
tgacaacaaa gttggccacc a 
<2lO> SEQ ID NO 13 
<2ll> LENGTH: 21 
<2l2> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l3 
gacaacaaag ttggccacca a 
<2lO> SEQ ID NO 14 
<2ll> LENGTH: 26 
<2l2> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l4 
gaattcgaca acaaagttgg ccacca 
<2lO> SEQ ID NO 15 
<2ll> LENGTH: 18 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l5 
tgggacaaca cctggaac 
<2lO> SEQ ID NO 16 
<2ll> LENGTH: 18 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l6 
ggacaacacc tggaacaa 
21 
21 
26 
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<2lO> SEQ ID NO 17 
<2ll> LENGTH: 16 
<2l2> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l7 
ggacaacacc tggaac l6 
<2lO> SEQ ID NO 18 
<2ll> LENGTH: 18 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l8 
gggacaacac ctggaaca l8 
<2lO> SEQ ID NO 19 
<2ll> LENGTH: 19 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: l9 
gggacaacac ctggaacaa l9 
<2lO> SEQ ID NO 20 
<2ll> LENGTH: 19 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 2O 
tgggacaaca cctggaaca l9 
<2lO> SEQ ID NO 21 
<2ll> LENGTH: 17 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 21 
ggacaacacc tggaaca l7 
<2lO> SEQ ID NO 22 
<2ll> LENGTH: 17 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 22 
gggacaacac ctggaac l7 
<2lO> SEQ ID NO 23 
<2ll> LENGTH: 21 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
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<400> SEQUENCE: 23 
gtgggacaac acctggaaca a 
<210> SEQ ID NO 24 
<211> LENGTH: 21 
<212> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 24 
tgggacaaca cctggaacaa g 
<210> SEQ ID NO 25 
<211> LENGTH: 26 
<212> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 25 
gaattctggg acaacacctg gaacaa 
<210> SEQ ID NO 26 
<211> LENGTH: 21 
<212> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 26 
ttgggtcctg aggcaacact c 
<210> SEQ ID NO 27 
<211> LENGTH: 21 
<212> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 2'7 
gggtcctgag gcaacactcg g 
<210> SEQ ID NO 28 
<211> LENGTH: 19 
<212> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 28 
gggtcctgag gcaacactc 
<210> SEQ ID NO 29 
<211> LENGTH: 21 
<212> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 29 
tgggtcctga ggcaacactc g 
<210> SEQ ID NO 30 
<211> LENGTH: 22 
21 
21 
26 
21 
21 
19 
21 
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<2l2> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 3O 
tgggtcctga ggcaacactc gg 
<2lO> SEQ ID NO 31 
<2ll> LENGTH: 22 
<2l2> TYPE: DNA 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 31 
ttgggtcctg aggcaacact cg 
<2lO> SEQ ID NO 32 
<2ll> LENGTH: 20 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 32 
gggtcctgag gcaacactcg 
<2lO> SEQ ID NO 33 
<2ll> LENGTH: 20 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 33 
tgggtcctga ggcaacactc 
<2lO> SEQ ID NO 34 
<2ll> LENGTH: 24 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 34 
gttgggtcct gaggcaacac tcgg 
<2lO> SEQ ID NO 35 
<2ll> LENGTH: 24 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 35 
ttgggtcctg aggcaacact cgga 
<2lO> SEQ ID NO 36 
<2ll> LENGTH: 15 
<2l3> ORGANISM: Artificial Sequence 
<220> FEATURE: 
<223> OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 36 
22 
22 
24 
24 
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—cont inued 
caacaaagtt ggcca 
SEQ ID NO 37 
LENGTH: 20 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 3'7 
catgacaaca aagttggcca 
SEQ ID NO 38 
LENGTH: 20 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 38 
ggtgggacaa cacctggaac 
SEQ ID NO 39 
LENGTH: 12 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 39 
acaacacctg ga 
SEQ ID NO 40 
LENGTH: 12 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Chemically synthesized 
<400> SEQUENCE: 4O 
caacacctgg aa 
15 
l2 
12 
What is claimed is: 
1. An isolated oligonucleotide consisting of SEQ ID NO: 
1 
2. An isolated oligonucleotide consisting of SEQ ID NO: 
2 
3. An isolated oligonucleotide consisting of SEQ ID NO: 
42, Wherein the oligonucleotide is capable of amplifying 
MTB complex DNA When used in conjunction With SEQ ID 
NO: 1 in a polymerase chain reaction. 
4. An isolated oligonucleotide capable of being a hydroly 
sis probe for the oligonucleotide primer pair of SEQ ID 
NOs: l and 2, Wherein said oligonucleotide consists of the 
sequence of SEQ ID NO: 3 or SEQ ID NO: 43. 
5. A kit for detecting MTB complex DNA comprising a 
?rst isolated oligonucleotide consisting of SEQ ID NO: 1 
and a second oligonucleotide selected from an oligonucle 
otide consisting essentially SEQ ID NO: 41 or SEQ ID NO: 
42. 
6. A kit for detecting MTB complex DNA comprising a 
?rst isolated oligonucleotide consisting of SEQ ID NO: 2 
45 
50 
60 
65 
and a second oligonucleotide selected from an oligonucle 
otide consisting essentially of SEQ ID NO:4l or SEQ ID 
NOz43. 
7. A kit for detecting MTB complex DNA comprising a 
?rst isolated oligonucleotide consisting of SEQ ID NO: 1 
and a second oligonucleotide consisting of SEQ ID NO: 2. 
8. A kit for detecting MTB complex DNA comprising a 
?rst oligonucleotide selected from the group consisting of: 
(A) an isolated oligonucleotide consisting of the sequence 
SEQ ID NO: 1; 
(B) and a second oligonucleotide selected from the group 
consisting of: 
1. an isolated oligonucleotide consisting of SEQ ID 
NO: 2; 
2. an isolated oligonucleotide consisting of 14 to 26 
nucleotides, 
Wherein said oligonucleotide hybridizes the complement 
of a sequence consisting of SEQ ID NO: 2 under 
stringent conditions, Wherein said oligonucleotide is 
capable of amplifying MTB complex DNA When used 
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in conjunction With SEQ ID NO: 1 in a polymerase 9. The kit of claims 7 or 8 further comprising a third 
chain reaction; and isolated oligonucleotide consisting of SEQ ID NO: 3 or SEQ 
3. an isolated oligonucleotide consisting of SEQ ID ID NO: 43. 
NO: 42, and Wherein the oligonucleotide is capable 10. The kit of claims 7 or 8 further comprising a PCR 
of amplifying MTB complex DNA When used in 5 reaction bulTer and DNA polymerase enzyme. 
conjunction With SEQ ID NO: 1 in a polymerase 
chain reaction. * * * * * 
